Providing investors with the
tools to make informed decisions.
Providing investors with the
tools to make informed decisions.
 Tracking 1053 U.S. listed China Stocks and Counting...
 Tracking 1535 U.S. Stocks and Counting...

 Sinobiopharma (PINK:SNBP)

At least one FIE exists in the corporate structure

Company Description

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

The company has developed new methods for synthesis of active pharmaceutical ingredient (“API”) and innovative drug delivery (new formulation) that dramatically reduces the time and cost of drug development. Our current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Our R&D focus is new, innovative methods of synthesizing compounds more rapidly at lower cost, and/or improved drug formulation with enhanced usability. In November 2009, we got the final approval from all authourities for the production and sales of our new drug Perindopril with brand name of Yitai. Yitai is a cardiovascular drug used for the patients with heart disease and high blood pressure. It is covered by Chinese health insurance.

Last updated July 23, 2008